The Arab pharmaceutical market is reportedly valued at more than $12 billion and is growing at more than 10% a year, with around 450 manufacturers. With the exception of Egypt, all Arab countries are high importers of branded drugs, while local manufacturing capabilities are limited to generic and licensed drugs with very little research and development. Thus, it has become more important for trade mark owners to address the challenges of pharmaceutical trade mark protection, and to become more familiar with the requirements that are specific to this region.